Celularity Inc
About Celularity Inc
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $26.6M
- Net income
- -$91.7M
- Total assets
- $107.3M
- Market cap
- $25.2M
- Gross margin
- 72.4%
- Operating margin
- -70.7%
- Net margin
- -106.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $54.2M
- Cost of revenue
- $15.0M
- Gross profit
- $39.2M
- Operating expenses
- $77.6M
- Operating income
- -$38.4M
- Net income
- -$57.9M
- EPS (basic)
- $-2.64
- EPS (diluted)
- $-2.64
Balance sheet
- Total assets
- $132.7M
- Current assets
- $20.6M
- Total liabilities
- $123.8M
- Current liabilities
- $53.7M
- Shareholders’ equity
- $8.8M
Cash flow
- Operating cash flow
- -$6.4M
- Investing cash flow
- $514.0K
- Financing cash flow
- $6.7M
- Net cash flow
- $814.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $25.2M
- EPS (diluted)
- $-2.64
- Shares outstanding
- 31.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 19, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $91.7M in FY2025.
- Revenue grew 154% from FY2021 to FY2024.
- Gross margin of 72.4%, net margin -106.8%.
- Trading 80% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Celularity Inc.
Write a review
News about Celularity Inc
News & sentiment via Polygon.io
